Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles (2014 - 2022)
Lineage Cell Therapeutics (LCTX) posted quarterly Amortizatization of Intangibles of -$3000.0 for Q2 2022, down 130.0% year-over-year from $10000.0 in Q2 2021, and up 25.0% quarter-over-quarter from -$4000.0 in Q1 2022.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles (2014 - 2022) Analysis & Trends
Lineage Cell Therapeutics' Amortizatization of Intangibles history runs 8 years deep, the most recent figure standing at -$3000.0 for Q2 2022.
- In Q2 2022, Amortizatization of Intangibles fell 130.0% year-over-year to -$3000.0; the TTM figure through Jun 2022 stood at -$13000.0 (down 117.57% YoY), while the FY2021 annual figure was $14000.0, down 80.56% from the prior year.
- Amortizatization of Intangibles for Q2 2022 stood at -$3000.0, up from -$4000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $70000.0 in Q4 2019, with the low at -$5000.0 in Q4 2021.
- The 4-year median for Amortizatization of Intangibles is $10000.0 (2021), against an average of $14857.1.
- The sharpest annual moves came in 2021 and 2022: Amortizatization of Intangibles climbed 11.11% in 2021, then tumbled 140.0% in 2022.
- Lineage Cell Therapeutics' Amortizatization of Intangibles stood at $70000.0 in 2019, then sank by 64.29% to $25000.0 in 2020, then slumped by 120.0% to -$5000.0 in 2021, then jumped by 40.0% to -$3000.0 in 2022.
- Business Quant data shows LCTX's Amortizatization of Intangibles at -$3000.0 in Q2 2022, -$4000.0 in Q1 2022, and -$5000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -3,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -5,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 29,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 9,000.00 |
| Dec 31, 2019 | 70,000.00 |
| Sep 30, 2019 | 32,000.00 |
| Jun 30, 2019 | 13,000.00 |
| Mar 31, 2019 | 14,000.00 |
| Jun 30, 2017 | 387,000.00 |
| Mar 31, 2017 | 253,000.00 |
| Dec 31, 2016 | 184,000.00 |
| Sep 30, 2016 | 19,000.00 |
| Jun 30, 2016 | 180,000.00 |
| Mar 31, 2016 | 65,000.00 |